Connect with us
Oryzon Genomics reported a loss of €2.4 million in the first half of 2024, slightly less than the €2.5 million loss in 2023. Financial losses decreased...
PharmaMar's turnover rose 0.8% in H1 2024, reaching €80.8 million, with oncology sales down 3.2%. Royalty income increased by 16%, while non-recurring income slightly declined. R&D...
The Metex Nøøvistago factory has been saved by the Avril group, but the initial biotech project to develop new chemical processes has been abandoned, marking a...
Sartorius Stedim Biotech reported a slight revenue decrease and significant drops in net profit and EBITDA for the first half of 2024, leading to a cautious...
Catalan start-up Made of Genes, specializing in personalized precision healthcare, plans to expand to the Middle East and the US. Already operating in Spain, Portugal, Andorra,...
Integra Therapeutics is a biotechnology company that creates genetic writing tools to improve the safety and efficacy of advanced therapies. The EC will invest in the...
Vytrus Biotech reported a 28% sales increase in H1 2024, reaching €2.5 million, with EBITDA rising 38% to nearly €1 million. The growth was driven by...
Moody's withdrew Grifols' ratings, citing "insufficient or inadequate" information amid a potential takeover by family shareholders and Brookfield fund. Grifols' shares dropped, with Class A down...
The new 500-square-metre Cantabria Labs R&D space at MaSID features cutting-edge infrastructure for developing new ingredients and technologies. This facility will enhance research and formulation for...
Esteve has expanded internationally by acquiring HRA Pharma Rare Diseases from Perrigo Company plc, adding three drugs for treating Cushing's syndrome and adrenocortical carcinoma. This €275...
 |
|
 |  |
 |
|